Pharmacoresistance remains a major problem for 30-40 % of patients with temporal lobe epilepsy. Furthermore, the marketed drugs are not completely without side effects. Therefore, the search for new therapies with a safer therapeutic index and better efficacy is clearly warranted. In the current study, we want to screen connexin43 hemichannels (Cx43-HCs) as novel antiepileptic drug targets through the application of TAT-Gap19, a newly developed and selective Cx43-HC inhibitor.
|Title of host publication||PhD day Center for Neurosciences (C4N)|
|Publication status||Published - May 2015|
|Event||Phd day center for neurosciences - Jette, Belgium|
Duration: 27 May 2015 → 27 May 2015
|Conference||Phd day center for neurosciences|
|Period||27/05/15 → 27/05/15|